IPHA stock news · Innate Pharma
Get alerts for IPHA
Follow Innate Pharma (IPHA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IPHAFree on the App Store and Google Play, or on the web.
Innate Pharma shared early Phase 1 study results for IPH4502, showing it fights tumors and has stable linkers.
NeutralInnate Pharma shared early IPH4502 trial observations and a linker-stability milestone, but gave no response figures or explained their effect. This does not yet change how we read the company.
Innate Pharma will join two healthcare conferences to talk with investors.
NeutralInnate Pharma will attend 2 healthcare conferences to discuss its immunotherapy pipeline. The story reports no new results or company changes, so it does not change the company's outlook.